WJPR Citation New

  All Since 2011
 Citation  2903  2393
 h-index  27  24
 i10-index  68  60

Login

Best Paper Awards

World Journal of Pharmaceutical Research (WJPR) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.
Best Paper Award :
Dr. Dhrubo Jyoti Sen
Download Article: Click Here

Search

Track Your Article

Abstract

REVIEW OF CLINICAL USE OF MONOCLONAL ANTIBODIES (BEVACIZUMAB)

Novia Fahrina Purnama Sari*, Made Dwike Swari Santi, Cece Furwanti, Anggara Martha Pratama and Farida Ulfa

Abstract

Bevacizumab is a humanized monoclonal antibody that has several potentials as a single agent or in combination with a chemotherapeutic agent. The first used in metastatic colorectal cancer (mCRC) therapy, metastatic breast cancer (mBC) therapy, and non-small cell lung cancer (NSCLC) therapy. Furthermore, there is evidence of clinical use for antiangiogenic therapy, as assessed by endothelial cell proliferation and tubule formation and widely accepted as first-line therapy in combination with chemotherapy. Due to the clinical validation of bevacizumab as a specific inhibitor of the interaction between VEGFA and VEGFR2, the increasing number of monoclonal antibodies in development has targeted VEGFR2 as a promising molecular target for anti-angiogenesis.

Keywords: Bevacizumab, monoclonal antibodies, VEGF-A, VEGFR2, and angiogenesis.


[Full Text Article]

Call for Paper

World Journal of Pharmaceutical Research (WJPR)
Read More

Email & SMS Alert

World Journal of Pharmaceutical Research (WJPR)
Read More

Article Statistics

World Journal of Pharmaceutical Research (WJPR)
Read More

Online Submission

World Journal of Pharmaceutical Research (WJPR)
Read More